Suppr超能文献

酪氨酸激酶抑制剂、机器人辅助部分肾切除术和转移灶切除术联合治疗有效应对伴有多发骨转移的肾细胞癌。

Renal cell carcinoma with multiple bone metastases effectively treated by a combination of tyrosine kinase inhibitor, robot-assisted partial nephrectomy, and metastasectomy.

作者信息

Sawada Atsuro, Takeda Masashi, Goto Takayuki, Akamatsu Shusuke, Kobayashi Takashi

机构信息

Department of Urology Kyoto University Graduate School of Medicine Kyoto Japan.

Department of Urology Nagoya University Graduate School of Medicine Nagoya Japan.

出版信息

Clin Case Rep. 2024 Mar 1;12(3):e8482. doi: 10.1002/ccr3.8482. eCollection 2024 Mar.

Abstract

KEY CLINICAL MESSAGE

Maintaining a disease-free status for a long time in cases of renal cell carcinoma with multiple bone metastases and repeated recurrences is challenging. What matters most in the multidisciplinary approach is the treatment strategy. Although this is a case where multidisciplinary treatment resulted in long-term CR during the TKI era, the treatment strategy is still relevant now that treatment options have increased.

ABSTRACT

Recent advances in medications, such as immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs), have improved metastatic renal cell carcinoma (mRCC) outcomes. We report a case of mRCC with bone metastasis that was successfully treated using a multidisciplinary approach. Here, we present a case of a 56-year-old man with left renal cancer and large and painful bone metastases at the 11th thoracic vertebrae (Th11). Therefore, a metastasectomy of Th11 was performed. Systemic treatment with TKI, robot-assisted partial nephrectomy, and metastasectomy were then administered. No recurrence was observed in >2 years. Long-term disease-free survival with the TKI-era multidisciplinary approach in a patient with mRCC remains significant when considering treatment sequences, especially now that drug treatment options-including ICIs-have increased. Treatment strategy and indication and timing of resection of the primary lesion and metastasectomy should be carefully considered in each case.

摘要

关键临床信息

对于伴有多发骨转移且反复复发的肾细胞癌患者,长期维持无病状态具有挑战性。在多学科治疗方法中,最重要的是治疗策略。尽管这是一例在酪氨酸激酶抑制剂(TKI)时代多学科治疗导致长期完全缓解(CR)的病例,但鉴于治疗选择增多,该治疗策略目前仍然适用。

摘要

免疫检查点抑制剂(ICI)和酪氨酸激酶抑制剂(TKI)等药物的最新进展改善了转移性肾细胞癌(mRCC)的治疗效果。我们报告一例采用多学科方法成功治疗的mRCC骨转移病例。在此,我们介绍一例56岁男性患者,患有左肾癌,第11胸椎(Th11)出现巨大且疼痛的骨转移。因此,对Th11进行了转移灶切除术。随后进行了TKI全身治疗、机器人辅助部分肾切除术和转移灶切除术。2年多未见复发。考虑到治疗顺序,尤其是现在包括ICI在内的药物治疗选择增多,TKI时代多学科方法在mRCC患者中实现长期无病生存仍然意义重大。每种情况都应仔细考虑治疗策略、原发灶切除和转移灶切除术的指征及时机。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acc8/10907337/425258fed9da/CCR3-12-e8482-g005.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验